VR Logo

Gemini Therapeutics Inc. (GMTX) download report


Healthcare | Biotechnology & Pharma Research

Gemini Therapeutics Inc. (GMTX) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD).

IPO Date: 12-Aug-2020

Interim Pres & CEO and Exec. Chairperson: Dr. Georges Gemayel C.F.A., Ph.D.

Chief Bus. Officer, CFO, Principal Accounting & Principal Financial Officer: Mr. Brian Piekos

Listing: NASDAQ: GMTX

Country: United States

Headquarters: Cambridge, MA

Website: https://www.geminitherapeutics.com

Key Facts

Market cap: $69.16 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-68.05 Mln

Cash: $119.06 Mln

Total Debt: $0.00 Mln

Insider's Holding: 11.41%

Liquidity: Low

52 Week range: $1.16 - 6.74

Shares outstanding: 43,227,200

Stock Performance

Time Period Gemini Therapeutics (GMTX) S&P BSE Sensex* S&P Small-Cap 600*
YTD-45.02-8.74-17.79
1 month17.65-2.01-2.72
3 months11.11-7.32-12.17
1 Year-76.080.45-15.82
3 Years--10.327.14
5 Years--11.296.20
10 Years--12.1410.33
As on 24-Jun-2022 *As on 27-Jun-2022
Year Gemini Therapeutics (GMTX) S&P Small-Cap 600 S&P BSE Sensex
2021-73.5525.2721.99